Literature DB >> 25163843

Direct role of antibody-secreting B cells in the severity of chronic hepatitis B.

Ayaid Khadem Zgair1, Jenan A Ghafil, Razaq H E Al-Sayidi.   

Abstract

Chronic hepatitis B involves different immune cells. The direct role of antibody-secreting B cells in the severity of chronic hepatitis B unclear. In this study, the number of plaque forming cells [PFC-(IgG, IgM, anti-HBc IgG, and anti-HBc IgM)], liver function tests (LFT) [alkaline phosphatase (ALP), alanine aminotransferase (ALT), and total serum bilirubin (TSB)], the levels of IL-10 in sera and in lymphocyte cultures, the number of CD4(+) and CD8(+) cells were measured in the peripheral blood of patients and in the controls. In addition, the hepatocytotoxic effect of anti-HBc and anti-HBe in vitro was studied. The largest number of PFCs was observed in the peripheral blood of patients with chronic hepatitis B. This was concomitant with a decrease in CD4(+) /CD8(+) ratio versus this ratio in asymptomatic HBV carriers and in healthy volunteers (P < 0.05). An increase in immunoglobulin (IgG and IgM) levels, anti-HBc IgG, and anti-HBc IgM levels and LFTs in peripheral blood of patients with chronic hepatitis B was seen. Anti-HBc induced hepatocytotoxicity in vitro. The expression of mRNA and protein for IL-10 production was observed at a significant level in culture of lymphocytes isolated from patients with chronic hepatitis B. In addition, a high level of IL-10 was found only in the sera of patients with chronic hepatitis B. It is concluded that the antibody-secreting B cells and the antibodies, which are produced, play an important role in the severity of chronic hepatitis B, which was related negatively with CD4(+) /CD8(+) ratio and positively with IL-10 expression.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  IL-10; T lymphocytes; chronic hepatitis B; liver function tests; plaque forming cells

Mesh:

Substances:

Year:  2014        PMID: 25163843     DOI: 10.1002/jmv.24067

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  10 in total

1.  Hepatitis B core antibody and liver stiffness measurements predict HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients with minimally elevated alanine aminotransferase (ALT) levels.

Authors:  Xihua Fu; Haibo Lou; Fang Chen; Xueping Gao; Zhanzhou Lin
Journal:  Clin Exp Med       Date:  2020-02-12       Impact factor: 3.984

2.  Association of Hepatitis B Core-Related Antigen and Antihepatitis B Core Antibody With Liver Fibrosis Evolution in Human Immunodeficiency Virus-Hepatitis B Virus Coinfected Patients During Treatment With Tenofovir.

Authors:  Romuald Cruchet; Lorenza N C Dezanet; Sarah Maylin; Audrey Gabassi; Hayette Rougier; Patrick Miailhes; Caroline Lascoux-Combe; Julie Chas; Pierre-Marie Girard; Constance Delaugerre; Karine Lacombe; Anders Boyd
Journal:  Open Forum Infect Dis       Date:  2020-06-07       Impact factor: 3.835

3.  Baseline quantitative hepatitis B core antibody could strongly predict survival for patients with hepatocellular carcinoma undergoing transarterial chemoembolization.

Authors:  Guosheng Yuan; Yuchen Zhou; Hao Zhang; Junjie Wang; Nianhuan Yang; Yabing Guo; Dinghua Yang; Yuanping Zhou
Journal:  Int J Clin Exp Med       Date:  2015-08-15

4.  Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues.

Authors:  Rong Fan; Jian Sun; Quan Yuan; Qing Xie; Xuefan Bai; Qin Ning; Jun Cheng; Yanyan Yu; Junqi Niu; Guangfeng Shi; Hao Wang; Deming Tan; Mobin Wan; Shijun Chen; Min Xu; Xinyue Chen; Hong Tang; Jifang Sheng; Fengmin Lu; Jidong Jia; Hui Zhuang; Ningshao Xia; Jinlin Hou
Journal:  Gut       Date:  2015-01-13       Impact factor: 23.059

5.  Serum hepatitis B core antibody levels predict HBeAg seroconversion in chronic hepatitis B patients with high viral load treated with nucleos(t)ide analogs.

Authors:  Shaohang Cai; Zhandong Li; Tao Yu; Muye Xia; Jie Peng
Journal:  Infect Drug Resist       Date:  2018-04-03       Impact factor: 4.003

6.  Serum hepatitis B core antibody as a biomarker of hepatic inflammation in chronic hepatitis B patients with normal alanine aminotransferase.

Authors:  Jiyuan Zhou; Liuwei Song; Hong Zhao; Linlin Yan; Anlin Ma; Shibin Xie; Xuqing Zhang; Dazhi Zhang; Qing Xie; Guo Zhang; Jia Shang; Jun Cheng; Weifeng Zhao; Zhiqiang Zou; Mingxiang Zhang; Ningshao Xia; Guiqiang Wang
Journal:  Sci Rep       Date:  2017-06-05       Impact factor: 4.379

Review 7.  The Multiple Functions of B Cells in Chronic HBV Infection.

Authors:  Ying Cai; Wenwei Yin
Journal:  Front Immunol       Date:  2020-12-14       Impact factor: 7.561

8.  Baseline Quantitative Hepatitis B Core Antibody Titer Is a Predictor for Hepatitis B Virus Infection Recurrence After Orthotopic Liver Transplantation.

Authors:  Bin Lou; Guanghua Ma; Feifei Lv; Quan Yuan; Fanjie Xu; Yuejiao Dong; Sha Lin; Yajun Tan; Jie Zhang; Yu Chen
Journal:  Front Immunol       Date:  2021-10-27       Impact factor: 7.561

9.  Anti-HBc IgG Responses Occurring at the Early Phase of Infection Correlate Negatively with HBV Replication in a Mouse Model.

Authors:  Xuyang Wang; Yumeng Zhang; Yinyin Ben; Chao Qiu; Jing Wu; Wenhong Zhang; Yanmin Wan
Journal:  Viruses       Date:  2022-09-11       Impact factor: 5.818

10.  Clinical Non-invasive Model to Predict Liver Inflammation in Chronic Hepatitis B With Alanine Aminotransferase ≤ 2 Upper Limit of Normal.

Authors:  Shanshan Chen; Haijun Huang
Journal:  Front Med (Lausanne)       Date:  2021-06-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.